Literature DB >> 20455888

Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.

Richard I G Holt1, Robert C Peveler.   

Abstract

Hyperprolactinaemia is a common side effect in people receiving antipsychotics. The propensity to cause hyperprolactinaemia differs markedly between antipsychotics as a result of differential dopamine D(2) receptor-binding affinity and ability to cross the blood-brain barrier. Sexual dysfunction is common and under-recognized in people with severe mental illness and is in part caused by hyperprolactinaemia. There are a number of long-term consequences of hyperprolactinaemia, including osteoporosis. Regular monitoring before and during treatment will help identify those developing antipsychotic-induced hyperprolactinaemia. The treatment includes dose reduction and change in antipsychotic. Where this is not possible because of the risk of relapse of the mental illness, sex steroid replacement may be helpful in improving symptoms secondary to hypogonadism and reducing the risk of osteoporosis. Tertiary prevention of complications should also be considered.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20455888     DOI: 10.1111/j.1365-2265.2010.03814.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.

Authors:  Anaïs Glatard; Monia Guidi; Aurélie Delacrétaz; Céline Dubath; Claire Grosu; Nermine Laaboub; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

2.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

3.  Factors affecting hospital stay in psychiatric patients: the role of active comorbidity.

Authors:  Athanassios Douzenis; Dionysios Seretis; Stella Nika; Paraskevi Nikolaidou; Athanassia Papadopoulou; Emmanouil N Rizos; Christos Christodoulou; Christos Tsopelas; Dominic Mitchell; Lefteris Lykouras
Journal:  BMC Health Serv Res       Date:  2012-06-19       Impact factor: 2.655

Review 4.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 5.  Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials.

Authors:  Meiling Meng; Wei Li; Shaowei Zhang; Hongyan Wang; Jianhua Sheng; Jijun Wang; Chunbo Li
Journal:  Shanghai Arch Psychiatry       Date:  2015-02-25

6.  Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.

Authors:  Qijing Bo; Fang Dong; Xianbin Li; Zhimin Wang; Xin Ma; Chuanyue Wang
Journal:  BMC Psychiatry       Date:  2016-11-09       Impact factor: 3.630

7.  Antipsychotics-induced hyperprolactinemia and screening for macroprolactin.

Authors:  Nedjeljka Ruljancic; Ana Bakliza; Sandra Vuk Pisk; Natko Geres; Katarina Matic; Ena Ivezic; Vladimir Grosic; Igor Filipcic
Journal:  Biochem Med (Zagreb)       Date:  2020-12-15       Impact factor: 2.313

Review 8.  The Correlation between Osteoporosis Occurrences in Both Schizophrenia and Parkinson's Disease.

Authors:  Fatemeh Radaei; Asma Darvishi; Shahriar Gharibzadeh
Journal:  Front Neurol       Date:  2014-06-02       Impact factor: 4.003

9.  Dopamine Autoreceptor Regulation of a Hypothalamic Dopaminergic Network.

Authors:  Stefanos Stagkourakis; Hoseok Kim; David J Lyons; Christian Broberger
Journal:  Cell Rep       Date:  2016-04-14       Impact factor: 9.423

10.  Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia.

Authors:  Lisanne M Geers; Ivan V Pozhidaev; Svetlana A Ivanova; Maxim B Freidin; Amand F Schmidt; Dan Cohen; Anastasiia S Boiko; Diana Z Paderina; Olga Yu Fedorenko; Arkadiy V Semke; Nikolay A Bokhan; Bob Wilffert; Jos G W Kosterink; Daan J Touw; Anton J M Loonen
Journal:  Br J Clin Pharmacol       Date:  2020-04-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.